NEW YORK (360Dx) – Beckman Coulter today announced it received CE marking for its high-sensitivity troponin (hsTnI) assay.

The Access hsTnI assay is to aid in diagnosing myocardial infarction in patients presenting with chest pains or other ischemic symptoms. Beckman Coulter Diagnostics Vice President and CMO Michael Samoszuk noted in a statement that the new assay provides greater precision at very low levels of troponin, giving clinicians "greater confidence in interpreting test results from patients seeking emergency care due to chest pain."

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.